Impact of Upadacitinib on Laboratory Parameters and Related Adverse Events in Patients with RA: Integrated Data Up to 6.5 Years.
Christina Charles-SchoemanJon T GilesNancy E LaneErnest H S ChoyDaniel E FurstJiri VencovskyAnthony G WilsonGerd-Rüdiger R BurmesterDerek CoombsSara K PennNasser KhanJillian B YeeKassim RahawiIain B McInnesPublished in: Rheumatology and therapy (2024)
The results of this integrated long-term analysis of laboratory parameters continue to support an acceptable safety profile of UPA 15 mg QD for moderate-to-severe RA.